There is a link between the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer and increased risk of Alzheimer disease, according to an analysis of electronic medical record data in a retrospective cohort of nearly 17,000 patients with prostate cancer.
Investigators extracted relevant data from the medical records, including medication lists and positive-present mention of drug and disease concepts from clinical notes. They then tested the effect of ADT use and duration on risk of Alzheimer disease.
Among the results:
• Nearly 2,400 patients received ADT during a median follow-up period of 2.7 years.
• There was a statistically significant link between ADT use and Alzheimer disease risk using both propensity score–matched and Cox regression analyses.
• There was also a significant increased risk of Alzheimer disease with longer duration of ADT.
Citation: Nead K, Gaskin G, Chester C, Swisher-McClure S, Leeper N, Shad N. Androgen deprivation therapy and future Alzheimer’s disease risk. [Published online ahead of print December 7, 2015] J Clin Oncol. doi:10.1200/JCO.2015.63.6266.